Summit Therapeutics (SMMT) was downgraded by Jefferies Financial Group Inc. from "buy" to "hold". They now have a $15.00 price target on the stock.
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]
Summit Therapeutics (SMMT) was upgraded by Zacks Research from "strong sell" to "hold".
Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]